SVB Securities analyst David Risinger lowered the firm’s price target on Amgen to $267 from $282 following the company’s January 31st Q4 results and 2023 guidance update. The firm keeps a Market Perform rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AMGN: